ASSESSING THE IMPACT OF EVOLUMAB ON BLOOD CHOLESTEROL LEVELS AND CARDIAC FUNCTION IN HYPERLIPIDEMIC ATHLETES

Abstract

Objective: This study aims to assess the impact of evolocumab on blood cholesterol levels and cardiac function in athletes with hyperlipidemia, offering insights into its potential benefits for maintaining cardiovascular health and athletic performance. Methods: One hundred hyperlipidemic patients treated at our hospital from January 2021 to March 2022 were randomly divided into two groups of fifty each: a control group treated with daily 10 mg simvastatin tablets, and an observation group receiving 140 mg of subcutaneous evolocumab injections weekly. Both groups received these treatments for three months alongside general medical care. We evaluated clinical efficacy by measuring changes in triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), and left ventricular ejection fraction (LVEF).Results: The clinical effective rate was significantly higher in the observation group (96.00%) compared to the control group (80.00%) (P<0.05). Both groups showed marked improvements in lipid profiles and cardiac function parameters; however, these improvements were more pronounced in the evolocumab-treated group. There was no significant difference in the incidence of adverse reactions between the groups (P>0.05). Logistic regression confirmed significant correlations between the clinical efficacy and the measured cholesterol and cardiac function indices. ROC curve analysis validated these indices as accurate predictors of clinical outcomes. Conclusion: Evolocumab significantly enhances clinical outcomes in the treatment of hyperlipidemia, effectively improving lipid profiles and cardiac function without increasing the risk of adverse reactions. For athletes, these results suggest that evolocumab could be particularly beneficial for managing hyperlipidemia with concurrent improvements in heart health, which is crucial for maintaining optimal physical performance. These findings advocate for the integration of evolocumab into cardiovascular management strategies for hyperlipidemic athletes, potentially extending their active careers and enhancing their quality of life.